LADENBURG THALM/SH SH Boosts ChromaDex (NASDAQ:CDXC) Price Target to $8.10

ChromaDex (NASDAQ:CDXC) had its target price raised by LADENBURG THALM/SH SH from $6.80 to $8.10 in a report issued on Wednesday morning,Benzinga reports. LADENBURG THALM/SH SH currently has a buy rating on the stock.

CDXC has been the topic of several other research reports. StockNews.com upgraded shares of ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 24th. Roth Mkm increased their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

ChromaDex Stock Up 52.7 %

Shares of NASDAQ CDXC opened at $8.55 on Wednesday. The firm’s 50-day moving average price is $5.68 and its 200-day moving average price is $5.13. The company has a market cap of $653.07 million, a PE ratio of 855.86 and a beta of 2.21. ChromaDex has a 52-week low of $1.57 and a 52-week high of $9.18.

Insider Transactions at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the sale, the director now owns 244,179 shares in the company, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On ChromaDex

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CDXC. USA Financial Formulas bought a new stake in ChromaDex during the 4th quarter worth approximately $25,000. State of Wyoming bought a new stake in ChromaDex during the 4th quarter worth approximately $39,000. Mercer Global Advisors Inc. ADV bought a new stake in ChromaDex during the 4th quarter worth approximately $53,000. Truist Financial Corp bought a new stake in ChromaDex during the 4th quarter worth approximately $54,000. Finally, FMR LLC bought a new stake in ChromaDex during the 3rd quarter worth approximately $55,000. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.